ReviewFrontiers in pharmacology2023
Advances in the pharmacological effects and molecular mechanisms of emodin in the treatment of metabolic diseases.
Review in Frontiers in pharmacology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Ferroptosis inhibition and mitochondrial rescue: a novel mechanism of emodin in rheumatoid arthritis.Redox report : communications in free radical research · 2026Article
- Aloe-Emodin Modifies Adipogenic Genes and the Expression of miR-143 and miR-155 in 3T3-L1 Cells.Life (Basel, Switzerland) · 2026Article
- Reprogramming macrophage metabolism for cardiovascular therapy: From molecular pathways to precision nanomedicine.Materials today. Bio · 2026Review
- An Integrated Study Based on UPLC-QTOF/MS Network Pharmacology and In Vivo Validation of the Anti-Obesity Effects of the 60% Ethanol-Eluted Fraction fromPlants (Basel, Switzerland) · 2026Article
- Dendrobium officinale polysaccharide ameliorate hyperlipidemia through LKB1/AMPK and CD36/PGC-1α/UCP1 activation and gut microbiota modulation.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Structural Characterization of an α-D-glucan fromMarine drugs · 2026Article
- Emodin and the Anthraquinone Scaffold: Therapeutic Promise and Strategies to Overcome Translational Barriers.Molecules (Basel, Switzerland) · 2026Review
- Osteoporosis: molecular pathogenesis and therapeutic interventions.Molecular biomedicine · 2025Review
- Mechanistic insights into the multi-target anti-atherosclerotic actions of rhubarb: a traditional remedy revisited.Chinese medicine · 2025Review
- Current status and trend of global research on the pharmacological effects of emodin family: bibliometric study and visual analysis.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- Emodin and Aloe-Emodin Reduce Cell Growth and Disrupt Metabolic Plasticity in Human Melanoma Cells.Nutrients · 2025Article
- Research progress on the regulatory effects and mechanisms of natural active products on intestinal barrier function.Frontiers in pharmacology · 2025Review
- Article
- Anthraquinones fromDrug design, development and therapy · 2025Review
- Metabolites of traditional Chinese medicine targeting PI3K/AKT signaling pathway for hypoglycemic effect in type 2 diabetes.Frontiers in pharmacology · 2024Review
- Effects of Cinnamon (Nutrients · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.